Jolien Suurmond

researcher ORCID ID = 0000-0002-4092-8925

Jolien Suurmond is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0002-4092-8925

P69educated atLeiden UniversityQ156598
P108employerThe Feinstein Institute for Medical ResearchQ7733638
P735given nameJolienQ21647026
JolienQ21647026
P106occupationresearcherQ1650915

Reverse relations

author (P50)
Q58234722Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses
Q44288937Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells
Q27024588Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity
Q34700290Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
Q51063130Communication between human mast cells and CD4(+) T cells through antigen-dependent interactions.
Q41494236Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering.
Q48258497Expansion of Th17 Cells by Human Mast Cells Is Driven by Inflammasome-Independent IL-1β.
Q40010797Human mast cells costimulate T cells through a CD28-independent interaction
Q44056900IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activation.
Q42575994Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium
Q38460407Mast cells in rheumatic disease.
Q58223827Repeated FcεRI triggering reveals modified mast cell function related to chronic allergic responses in tissue
Q39371149The production and secretion of complement component C1q by human mast cells
Q38391522Therapeutics to block autoantibody initiation and propagation in systemic lupus erythematosus and rheumatoid arthritis.
Q58234718Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies

Search more.